LY3962673

LY3962673 · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3962673, covering 2026-04-20 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors [Phase 1]